Research and Markets has announced the addition of the "DNA Gyrase Subunit B (EC 184.108.40.206) - Pipeline Review, H1 2016" report to their offering.
DNA Gyrase Subunit B (EC 220.127.116.11) pipeline target constitutes close to 7 molecules, out of which approximately 7 molecules are developed by companies.
Furthermore, DNA Gyrase Subunit B (EC 18.104.22.168) DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks supertwisting activity.
The report 'DNA Gyrase Subunit B - Pipeline Review, H1 2016' outlays comprehensive information on the DNA Gyrase Subunit B (EC 22.214.171.124) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in DNA Gyrase Subunit B (EC 126.96.36.199) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2 and 1 respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/25k677/dna_gyrase
Related Topics: Enzymes
View source version on businesswire.com: http://www.businesswire.com/news/home/20160831005776/en/Business Wire
Last updated on: 31/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.